KEYNOTE-905 ad hoc analysis:
EV + pembrolizumab vs pembrolizumab alone suggests that EV plays a key role in the neoadjuvant setting.
But is adjuvant EV really necessary?
Hopefully, VOLGA will provide some clues tomorrow!
#ESMO26
229 浏览 · 1 赞 · 2 转发 · 0 回复
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.org来源：Kohji Takemura, MD · x.com